^
Association details:
Biomarker:No biomarker
Cancer:Burkitt Lymphoma
Regimen:RIVAC (cytarabine + etoposide IV + ifosfamide + Rituxan (rituximab))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Burkitt lymphoma: suggested treatment regimens…second-line therapy…other recommended regimens…RIVAC (rituximab, ifosfamide, cytarabine, etoposide)…